(480) 923-0802
Join Our Panel
Consulting
Insights
Podcast
DVI
About
Contact Us
Posts Tagged ‘Alzheimer’s
All Categories
Our Take Newsletter
Downloadable Articles
By the Numbers
October 10, 2022
Our Take: Amylyx’s investigational ALS drug gains FDA approval, but the controversy continues
Read More
October 03, 2022
Our Take: Eisai, Biogen’s lecanemab slowed clinical decline by 27% in Phase III Alzheimer’s trial
Read More
July 19, 2021
Our Take: Oral arguments in Pfizer lawsuit renew focus on case that could have industry-wide implications
Read More
July 12, 2021
Our Take: As delta becomes dominant strain, U.S. COVID-19 cases increase nearly 11% in one week
Read More
June 28, 2021
Our Take: Blues plans fund new startup to address high drug prices
Read More
June 21, 2021
Our Take: Beaumont Health and Spectrum Health in talks to form a new 22-hospital health system
Read More
June 14, 2021
Our Take: FDA grants accelerated approval to Biogen’s Alzheimer’s drug, creating more controversy
Read More
October 28, 2019
Our Take: Biogen’s aducanumab gets a second life
Read More
June 03, 2019
Episode 52: Our Take, June 3, 2019
Read More
April 22, 2019
Our Take: Humana launches new oncology payment model
Read More
March 25, 2019
Our Take: A big week for Pharma
Read More
Sign up for Our Take
the weekly strategic brief for Health Care Executives
Please leave this field empty
Business Email
*
Check your inbox or spam folder to confirm your subscription.
share
Contact Darwin Research Group and we will get right back to you.
Please leave this field empty.
Consulting
Insights
Podcast
DVI
About
Contact Us